Confo Therapeutics and DyNAbind GmbH entered a drug discovery collaboration on an undisclosed G-protein coupled receptor (GPCR).
 
The collaboration will combine ConfoBody-enabled GPCRs with DyNAbind’s Dynamic DNA-encoded Library for the discovery of small molecule GPCR-modulating compounds. Under the terms of the agreement, Confo Therapeutics will gain exclusive, worldwide rights to any drug candidates arising from the collaboration and will be responsible for their development, manufacturing and commercialization.  
 
“This collaboration will leverage the combination of two cutting-edge technologies to expand our universe of hits on a GPCR previously thought to be intractable,” said Christel Menet, chief scientific officer, Confo Therapeutics.

Michael Thompson, co-founder and chief executive officer, DyNAbind, said, “GPCRs are high-potential targets for drug discovery, but have been traditionally difficult to work with. Confo Therapeutics’ technology has proven itself to be a powerful tool for the stabilization of GPCRs in a particular conformation. Partnered with the increased signal-to-noise ratios seen with our Dynamic Library technology, we are in a strong position to identify drug candidates against this specific target.”